Safer Alternatives and Evidence-Based Treatment Options MHRA-licensed options including semaglutide (Wegovy), liraglutide (Saxenda), orlistat, and tirzepatide (Mounjaro) offer evidence-based weight management with well-characterised safety profiles and defined NICE eligibility criteria
Not everybody will require the same thing at the same time over their journey with obesity and related comorbidities that can be 20, 40 even 60 years long. + How Roche passed on a potential $14 billion-a-year weight-loss pill Roche was among the first pharmaceutical companies to research drugs in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest GLP-1 boom began
Among these patients who both take a GLP-1 and have diabetes, the average age is 59.2, and 73.5% are commercially insured
Throughout this post, we will cover the science behind GLP-1 receptors in the digestive tract, the specific impacts on diarrhea-predominant and constipation-predominant IBS, and the practical steps you can take to support your gut health while pursuing your weight loss goals
Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
This creates a wave pattern
